Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.

@article{Porkka2010Dasatinib1M,
  title={Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.},
  author={Kimmo V.K. Porkka and Hanna J Khoury and Ronald L. Paquette and Yousif H Matloub and Ritwik Sinha and Jorge E. Cortes},
  journal={Cancer},
  year={2010},
  volume={116 2},
  pages={
          377-86
        }
}
BACKGROUND Dasatinib, a highly potent BCR-ABL inhibitor, is an effective treatment for patients with chronic myeloid leukemia in chronic phase (CML CP) after resistance, suboptimal response, or intolerance to prior imatinib. In a phase 3 dose optimization trial in patients with CML CP (CA180-034), the occurrence of pleural effusion was significantly minimized with dasatinib 100 mg once daily (QD) compared with other treatment arms (70 mg twice daily [twice daily], 140 mg QD, or 50 mg twice… CONTINUE READING
Highly Cited
This paper has 105 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia

Journal of blood medicine • 2010
View 7 Excerpts
Highly Influenced

105 Citations

051015'11'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 105 citations based on the available data.

See our FAQ for additional information.